These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11000464)

  • 21. Acute respiratory infections (ARI) in children: prospects for prevention.
    Monto AS; Lehmann D
    Vaccine; 1998 Oct; 16(16):1582-8. PubMed ID: 9711807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbial interactions in the respiratory tract.
    Murphy TF; Bakaletz LO; Smeesters PR
    Pediatr Infect Dis J; 2009 Oct; 28(10 Suppl):S121-6. PubMed ID: 19918134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing a vaccine to prevent otitis media caused by nontypeable Haemophilus influenzae.
    Khan MN; Ren D; Kaur R; Basha S; Zagursky R; Pichichero ME
    Expert Rev Vaccines; 2016 Jul; 15(7):863-78. PubMed ID: 26894630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current progress of adhesins as vaccine candidates for Moraxella catarrhalis.
    Tan TT; Riesbeck K
    Expert Rev Vaccines; 2007 Dec; 6(6):949-56. PubMed ID: 18377357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute respiratory infections: the forgotten pandemic. Communiqué from the International Conference on Acute Respiratory Infections, held in Canberra, Australia, 7-10 July 1997.
    Int J Tuberc Lung Dis; 1998 Jan; 2(1):2-4. PubMed ID: 9562104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine.
    Hare KM; Smith-Vaughan HC; Leach AJ; Pizzutto SJ; McCallum GB; Chang AB
    Vaccine; 2018 Mar; 36(13):1736-1742. PubMed ID: 29478754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Oral administration of "Infectvac" for prevention of acute respiratory tract infections].
    Luther P; Brachmann I; Werchan D; Wittig C; Tischner H
    Z Erkr Atmungsorgane; 1990; 175(2):95-9. PubMed ID: 2264367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal vaccination against encapsulated respiratory bacteria--new potentials for conjugate vaccines?
    Jakobsen H; Jonsdottir I
    Scand J Immunol; 2003 Aug; 58(2):119-28. PubMed ID: 12869132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal immunization for bacterial respiratory infections.
    Cripps AW
    Hum Vaccin; 2008; 4(6):396-9. PubMed ID: 18838872
    [No Abstract]   [Full Text] [Related]  

  • 30. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
    Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacterial otitis media: current vaccine development strategies.
    Cripps AW; Kyd J
    Immunol Cell Biol; 2003 Feb; 81(1):46-51. PubMed ID: 12534945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccines for Moraxella catarrhalis and non-typeable Haemophilus influenzae.
    McMichael JC; Green BA
    Curr Opin Investig Drugs; 2003 Aug; 4(8):953-8. PubMed ID: 14508879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacteria from bronchoalveolar lavage fluid from children with suspected chronic lower respiratory tract infection: results from a multi-center, cross-sectional study in Spain.
    Escribano Montaner A; García de Lomas J; Villa Asensi JR; Asensio de la Cruz O; de la Serna Blázquez O; Santiago Burruchaga M; Mondéjar López P; Torrent Vernetta A; Feng Y; Van Dyke MK; Reyes J; Garcia-Corbeira P; Talarico CA;
    Eur J Pediatr; 2018 Feb; 177(2):181-192. PubMed ID: 29285648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacterial otitis media: a vaccine preventable disease?
    Cripps AW; Otczyk DC; Kyd JM
    Vaccine; 2005 Mar; 23(17-18):2304-10. PubMed ID: 15755616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of mucosal immunisation in pulmonary clearance of Moraxella (Branhamella) catarrhalis.
    Kyd J; John A; Cripps A; Murphy TF
    Vaccine; 1999 Oct; 18(5-6):398-406. PubMed ID: 10519928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant.
    Kodama S; Abe N; Hirano T; Suzuki M
    Laryngoscope; 2006 Feb; 116(2):331-5. PubMed ID: 16467729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life.
    Borges IC; Andrade DC; Cardoso MR; Toppari J; Vähä-Mäkilä M; Ilonen J; Knip M; Hyöty H; Veijola R; Simell O; Jartti T; Käyhty H; Ruuskanen O; Nascimento-Carvalho CM
    Clin Vaccine Immunol; 2016 Nov; 23(11):878-883. PubMed ID: 27581439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection.
    Murdin AD; Dunn P; Sodoyer R; Wang J; Caterini J; Brunham RC; Aujame L; Oomen R
    J Infect Dis; 2000 Jun; 181 Suppl 3():S544-51. PubMed ID: 10839756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus.
    Keller DW; Breiman RF
    Clin Infect Dis; 1995 Aug; 21 Suppl 1():S77-83. PubMed ID: 8547517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.